Study on the Treatment of ITP Mice with IVIG Sourced from Distinct Sex-Special Plasma (DSP-IVIG)
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242115993 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Wei Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Peking Union Medical College, Chengdu 610052, China. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Science and Technology of Sichuan Province, CAMS Innovation Fund for Medical Sciences, Scientific Research Project of Sichuan Medical Association.
Abstract (Originalsprache)
Intravenous immunoglobulin (IVIG) is a first-line drug prepared from human plasma for the treatment of autoimmune diseases (AIDs), especially immune thrombocytopenia (ITP). Significant differences exist in protein types and expression levels between male and female plasma, and the prevalence of autoimmune diseases varies between sexes. The present study seeks to explore potential variations in IVIG sourced from distinct sex-specific plasma (DSP-IVIG), including IVIG sourced from female plasma (F-IVIG), IVIG sourced from male plasma (M-IVIG), and IVIG sourced from a blend of male and female plasma (Mix-IVIG). To address this question, we used an ITP mouse model and a monocyte–macrophage inflammation model treated with DSP IVIG. The analysis of proteomics in mice suggested that the pathogenesis and treatment of ITP may involve FcγRs mediated phagocytosis, apoptosis, Th17, cytokines, chemokines, and more. Key indicators, including the mouse spleen index, CD16+ macrophages, M1, M2, IL-6, IL-27, and IL-13, all indicated that the efficacy in improving ITP was highest for M-IVIG. Subsequent cell experiments revealed that M-IVIG exhibited a more potent ability to inhibit monocyte phagocytosis. It induced more necrotic M2 cells and fewer viable M2, resulting in weaker M2 phagocytosis. M-IVIG also demonstrated superiority in the downregulation of surface makers CD36, CD68, and CD16 on M1 macrophages, a weaker capacity to activate complement, and a stronger binding ability to FcγRs on the THP-1 surface. In summary, DSP-IVIG effectively mitigated inflammation in ITP mice and monocytes and macrophages. However, M-IVIG exhibited advantages in improving the spleen index, regulating the number and typing of M1 and M2 macrophages, and inhibiting macrophage-mediated inflammation compared to F-IVIG and Mix-IVIG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Peking Union Medical College, Chengdu 610052, China.
ORCID-Profile: Zongkui Wang, Shengliang Ye, Rong Zhang
Förderung
- Department of Science and Technology of Sichuan Province
- CAMS Innovation Fund for Medical Sciences
- Scientific Research Project of Sichuan Medical Association
Zitieren
APA
Zhang, W., Yuan, X., Wang, Z., Xu, J., Ye, S., Jiang, P., Du, X., Liu, F., Lin, F., Zhang, R., Ma, L., & Li, C. (2023). Study on the Treatment of ITP Mice with IVIG Sourced from Distinct Sex-Special Plasma (DSP-IVIG). International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242115993
Vancouver
Zhang W, Yuan X, Wang Z, Xu J, Ye S, Jiang P, et al. Study on the Treatment of ITP Mice with IVIG Sourced from Distinct Sex-Special Plasma (DSP-IVIG). International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242115993
BibTeX
@article{Zhang2023,
author = {Zhang, Wei and Yuan, Xin and Wang, Zongkui and Xu, Jixuan and Ye, Shengliang and Jiang, Peng and Du, Xi and Liu, Fengjuan and Lin, Fangzhao and Zhang, Rong and Ma, Li and Li, Changqing},
title = {Study on the Treatment of ITP Mice with IVIG Sourced from Distinct Sex-Special Plasma (DSP-IVIG)},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242115993}
}
EUVIMED